Emphysematous Phenotype is Characterized by Low Blood Eosinophils: A Cross-Sectional Study. (2nd November 2017)

• Record Type: Journal Article
• Authors: Papaioannou, Andriana I.; Kostikas, Konstantinos; Papaporfyriou, Anastasia; Angelakis, Leonidas; Papathanasiou, Evgenia; Hillas, Georgios; Mazioti, Argyro; Bakakos, Petros; Koulouris, Nikolaos; Papiris, Spyros; Loukides, Stelios
• Is Part Of: COPD. Volume 14:Number 6(2017)
• Page Start: 635
• Page End: 640
• Publication Date: 2017-11-02
• Subjects: COPD -- emphysema -- eosinophils -- induced sputum -- high resolution computed tomography; Lungs -- Diseases, Obstructive -- Periodicals; 616.24
• DOI: 10.1080/15412555.2017.1386644
• Languages: English
• ISSNs: 1541-2555

Abstract

ABSTRACT: Sputum and blood eosinophils are proposed as candidate biomarkers for the identification of chronic obstructive pulmonary disease (COPD) patients at risk for exacerbation and treatment response. In this study, we evaluated the associations of eosinophils with the presence of emphysema in COPD patients. Induced sputum and blood eosinophil measurements were performed in consecutive COPD patients. Patients underwent lung function testing and high resolution computed tomography (HRCT) of the chest and the presence of emphysema was quantified. Patients with emphysematous lesions in ≥15% of the pulmonary parenchyma were considered having significant emphysema. Ninety-eight patients were included in the study. Patients with significant emphysema had lower blood eosinophil counts compared to patients without emphysema [median (IQR) 34.6 (0.0, 63.0) vs. 169.0 (110.0, 260.0) cells/µL, p < 0.001]; similar results were observed for the percentage (%) of blood eosinophils, but no difference was observed for sputum eosinophils. The differences were evident in frequent and non-frequent exacerbators and irrespective of the use of inhaled corticosteroids (ICS). Patients with significant emphysema in HRCT present lower levels of blood eosinophils and these differences were present irrespective of the frequent exacerbator history or the use of ICS. Blood eosinophils may not represent a clinically relevant biomarker in the presence of emphysema.